Furthermore, according to a study conducted in Japan, HER2-low breast cancer was observed to have a poorer prognosis in HR-positive patients compared to HER2-negative breast cancer, whereas no significant difference was noted in HR-negative patients (22). Here, ERBB2 is linked to breast carcinoma.